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Introduction
Migraine-associated vertigo (MV) is a relatively common 
condition that is often misdiagnosed in general practice, 
despite the fact that the condition can be managed medically 
and without neurological referral.1 Patients presenting with 
idiopathic dizziness are often misdiagnosed as suffering 
from anxiety, despite a history that may distinguish between 
psychogenic dizziness and migraine-associated dizziness 
(MD). Most studies on this condition have only been carried 
out during the past two decades,2 commencing with Kayan 
and Hood’s classic paper on the subject.3 To date there 
are no known studies investigating the prevalence of this 
debilitating illness in general practice in South Africa. The 
prevalence of MV in the United States is approximately 3.0–
3.5% of the population.4
Background
MV was originally diagnosed by Aretaeus of Cappadocia 
around 100 AD.5 However, this condition remains a 
developing entity, because there are no accepted diagnostic 
criteria.2 The International Headache Society (IHS)6 does not 
provide criteria for its diagnosis (see Tables I and II). The 
only available criteria are those proposed by Neuhauser et 
al7 which are modelled on the IHS classification of migraine 
(see Table III). The diagnosis in itself is based on history 
and not on special investigations. Special investigations do 
have a place where the index of suspicion for conditions 
such as multiple sclerosis is high.
Approximately 16% of adults are affected by migraine at 
some point in their lives, whereas the lifetime prevalence of 
dizziness is about 23%.2,8 In a recent study the prevalence 
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of migraine, according to IHS criteria, was found to be 1.6 
times higher in 200 patients in a dizziness clinic than in 200 
age- and sex-matched controls in an orthopaedic clinic 
(38% vs 24%, P 0.01).7 It has also been found that episodic 
vertigo occurs in 25–35% of all migraine patients.4
Patients may present with dizziness or true vertigo in 
the absence of headache, or the dizziness may precede 
the migraine, occur with a headache, or follow after it.4 
In some cases migraine attacks may have ceased in the 
patient’s younger years, whilst MV only manifests itself 
much later, predominantly when patients are in their 
thirties.1 Where dizziness or vertigo exist in the absence 
of headache, careful history taking may reveal a history of 
migraine, or concurrent symptoms such as photophobia 
and phonophobia, or auras. Interestingly, the dizziness 
may be triggered by dietary triggers, sleep disorders or 
lack of sleep, and hormonal changes such as premenstrual 
tension.2 Auras may present in the absence of headache 
and may include simple numbness of extremities, pins 
and needles, visual auras such as flashing lights, and even 
speech disturbances (see Table II).
The occurrence, with seemingly idiopathic dizziness 
with aura symptoms, may then lead to a diagnosis of 
psychogenic dizziness or anxiety if the physician neglects 
to ask the patient about headache or migraine symptoms. 
Once again, these symptoms may be obscure, because 
vertigo can be triggered by certain foods, or there can be an 
abnormal sensation in one or more limbs accompanying the 
major symptom, namely dizziness.6
A recent study identified a progesterone receptor variant as 
being significantly associated with MV, while no synergistic 
effect between the oestrogen receptor variant and MV was 
found.9 It is an interesting fact that most studies on MV 
show a clear female predominance that also correlates with 
the predominance of migraine in the female population.1,9,10 
There are studies linking an increased risk of stroke in 
females in their thirties that suffer from migraine with aura 
and use the oral contraceptive pill (OCP).11 For this reason 
use of the OCP is contraindicated in women suffering 
from migraine with aura. The aura phenomenon may well 
Table I: International Headache Society diagnostic criteria for migraine 
without aura
A.  At least 5 attacks fulfilling criteria B–D
B.  Headache attacks lasting 4–72 hours
C.  Headache has at least two of the following characteristics:
1.  Unilateral location
2.  Pulsating quality
3.  Moderate or severe pain intensity
4.  Aggravation by or causing avoidance of routine physical activity 
(walking or climbing stairs)
D.  During headache at least one of the following:
1.  Nausea and or vomiting
2.  Photophobia and/or phonophobia
E.  Not attributed to another disorder
Source: 
International Headache Society Classification Subcommittee. International classification of 
headache disorders. 2nd edn. Cephalalgia 2004:24 (Suppl 1):1–160.
http://ihs-classification.org
Table II: International Headache Society diagnostic criteria for typical aura 
with migraine headache
A.  At least two attacks fulfilling criteria B–D
B.  Aura consisting of at least one of the following but no motor 
weakness:
1.  Fully reversible visual symptoms including positive features (e.g. 
flickering lights, spots or lines) and/or negative features (i.e. loss of 
vision)
2.  Fully reversible sensory symptoms including positive features (i.e. 
pins and needles) and/or negative features (i.e. numbness)
3.  Fully reversible dysphasic speech disturbance
C.  At least two of the following:
1.  Homonymous visual symptoms and/or unilateral sensory symptoms
2.  At least one aura symptom develops gradually over more than or equal 
to 5 minutes and/or different aura symptoms occur in succession over 
more than or equal to 5 minutes
3. Each symptom lasts more than or equal to 5 minutes but less than or 
equal to 60 minutes
D.  Headache fulfilling criteria B–D for migraine without aura begins during 
the aura or follows the aura within 60 minutes
E.  Not attributed to another disorder
Source: 
International Headache Society Classification Subcommittee. International classification of 
headache disorders. 2nd edn. Cephalalgia 2004:24 (Suppl 1):1–160.
http://ihs-classification.org
Table III: The diagnostic criteria of Neuhauser et al for definite and 
probable migrainous vertigo
Diagnostic criteria for definite migrainous vertigo:
A. Episodic vestibular symptoms of at least moderate severity
B.  Current or previous history of migraine according to the 2004 criteria 
of the IHS
C.  One of the following migrane symptoms during two or more attacks of 
vertigo: migrainous headache, photophobia, phonophobia, visual or 
other auras
D.  Other causes ruled out by appropriate investigations
 Comment: Vestibular symptoms are rotational vertigo or another 
illusory self or object motion. They may be spontaneous or positional. 
Vestibular symptoms are moderate if they interfere with but do not 
prohibit daily activities and severe if patients cannot continue daily 
activities.
Probable migrainous vertigo:
A.  Episodic vestibular symptoms of at least moderate severity
B.  One of the following:
1.  Current or previous history of migraine according to the 2004 criteria 
of the IHS
2.  Migrane symptoms during vestibular symptoms
3.  Migraine precipitants of vertigo in more than 50% of attacks: food 
triggers, sleep irregularities, hormonal change
4.  Response to migraine medications in more than 50% of attacks
C.  Other causes ruled out by appropriate investigations
Source: 
Lempert T, Neuhauser H. Migrainous vertigo. Neurologic Clinics 23(2005):715–30.
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be linked to vasospasm and risk may be compounded 
where other stroke factors exist. Furthermore, episodes of 
transient hearing loss with or without associated vertigo 
have been reported in young women with migraine around 
the time of their menstrual period.12
Symptoms
Patients with MV often present with symptoms of chronic 
dizziness that may last for days or months, or just a 
couple of seconds. There is a bimodal distribution for the 
duration of symptoms, with most patients experiencing 
symptoms lasting minutes to hours, or all day and longer.1,13 
Dizziness or vertigo may be so debilitating as to severely 
restrict daily activities. Other symptoms may be a migraine 
headache preceding, during or after the vertigo, or it may 
be absent. Photophobia, phonophobia and visual auras 
may accompany the attack or may be absent. Vertigo 
may be spontaneous or positional.  Migraine precipitants 
may be present in more than 50% of attacks of dizziness. 
Precipitants can include food triggers like red wine, 
chocolate or cheese, sleep irregularities or lack of sleep, 
as well as hormonal changes such as premenstrual tension 
and oestrogen fluctuation or withdrawal.2,7 (See Table III).
Aura symptoms may include a subjective feeling of numbness 
in one or both limbs, ataxia or feeling off balance, dysphasia 
or dysarthria, a feeling of fullness or pressure in the ears, 
visual auras such as flashing lights or blindness, pins and 
needles in the face or limbs, photophobia, hyperaccusis, or 
even a sense of anxiety prior to the aura. Osmophobia or a 
hypersensitivity to smells is virtually diagnostic of migraine 
(see Table II).
MD and MV may also occur with history of migraine alone, 
making the diagnosis more difficult. In these cases a 
response to migraine medications may warrant a diagnosis 
of probable MV.2,7
Patients also eventually experience anxiety as a result of 
symptoms, and it may be misinterpreted as a cause of the 
symptoms. Furthermore, and to complicate matters, studies 
have proven a link between migraine and an increased 
risk of panic disorders and depression.2 Diagnostic fallacy 
often prevails when the physician fails to elicit a history of 
accompanying headaches or migraine precipitants.
Methods
A study was conducted to determine the prevalence 
of patients that presented with possible or definite MD 
and vertigo in a general medical practice. The study 
was conducted in a private medical practice in Pretoria. 
The duration of the study was from 12 January 2009 
to 12 September 2009. Patients were diagnosed as 
having migraine according to the IHS criteria of 2004,6 
and furthermore, definite or probable MV according to 
the diagnostic criteria of Lempert and Neuhauser2 and 
Neuhauser et al7 (see Table III). Patients with likely vestibular 
pathology or Ménière’s disease were excluded and patients 
with a medical condition or drug usage that could cause the 
symptoms were excluded. Patients were excluded if there 
was a strong suspicion of psychogenic dizziness or where 
the likelihood of an anxiety-related disorder was high.
No audiometric testing was carried out because this is 
not routinely done in general practice, but an otological 
(ear, nose and throat) examination and general medical 
examination (including measurement of blood pressure) 
were performed on each patient. The clinical presentation 
of MD is variable and the association with migraine may be 
subtle. Key to the diagnosis is the repeated concurrence 
of migraine symptoms and vertigo, migraine precipitants, 
and a response to antimigraine drugs and prophylactic 
medications.2 If there were other symptoms that could 
have indicated possible multiple sclerosis, patients were 
not included in the study unless they first had a magnetic 
resonance brain scan to rule out pathology attributable to 
multiple sclerosis.
Results
A total number of 866 patient visits were recorded. As 
some of these visits included patients that were seen more 
than once, a total number of 717 different patients were 
seen. Of these, 18 visits were related to dizziness that was 
diagnosed as being migraine associated. A total number 
of 12 patients out of 717 persons in the general examined 
population were diagnosed as having probable or definite 
MV as presenting complaint. Of these 12 patients, nine were 
female. Ages of the affected patients ranged from 14 to 50 
years. The average age of presentation was 34.0 years, 
which correlates well with Reploeg and Goebel’s reported 
average age of 36.6 years at presentation.1
All of the patients in the affected group fulfilled the criteria 
for definite or probable MV. Nine of the patients fulfilled the 
criteria for definite MV and three of the patients (2 females 
and 1 male) fulfilled the diagnostic criteria for probable MV 
(see Table IV). Seven patients experienced occasional pins 
and needles or numbness in the face or limbs, four patients 
experienced photophobia and three patients experience 
hyperaccusis. Three patients had occasional visual auras, 
one patient experienced occasional pressure in the ears, 
and one patient reported occasional speech disturbance 
(see Table V).
Of the 12 patients diagnosed, five patients desired and 
needed medical treatment. Amitriptyline and sodium 
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valproate are both used as migraine prophylactic drugs. 
Three patients used amitriptyline 25 mg nocte with sodium 
valproate controlled release formula 300 mg 12 hourly, in 
combination, and two patients used amitriptyline 25 mg 
nocte alone. All five of the treated patients had complete 
resolution of all symptoms within one month. (Note that 
the dosage of amitriptyline used was too low to have a real 
mood altering effect. Dosages of 75 mg and even 150 mg 
are used when the drug is used as an antidepressant.) Eight 
of the female patients used the OCP and the other female 
was on hormone replacement therapy (HRT). 
Discussion	and	pathophysiology
There are several theories for the pathophysiology of MV, 
despite the fact that it is poorly understood. There are 
theories that involve both central as well as peripheral 
defects. 
One of the most popular theories is that proposed by Cutrer 
and Baloh:13 episodes of dizziness in duration similar to 
that of aura (less than 60 minutes) that are time-locked with 
the headache are related to a spreading wave of cortical 
depression, the same as other aura phenomena. This theory 
proposes that a stimulus results in a transient wave that 
suppresses central neuronal activity. This stimulus spreads 
in all directions from its origin. Concomitantly there can be 
increases in intracellular potassium (K+) and decreases in 
extracellular calcium (Ca2+). These increases may lead to 
reduced cerebral blood flow in the areas where there is 
depression of cortex function. This theory is supported by 
studies in which sudden hearing loss is linked to migraine 
and attributed to vasospasm of the internal auditory artery.12 
Some authors propose that peripheral cochleovestibular 
dysfunction in migraine sufferers may similarly be due to 
vasospasm of the internal auditory artery, with possible 
ischaemia.4,17 This proposal may be more plausible in 
relation to patients who experience short attacks of MV.2 
The attacks of MV may, however, last for days or weeks 
in the majority of patients.1 A further problem is that most 
patients with MV have dizziness that shows no specific 
relation to the headache.2,4 Benson et al4 noted that changes 
in sensorineural hearing are rarely a significant feature of 
MV, but they rather help to differentiate it from other causes 
of vertigo, especially Ménière’s disease.
Reploeg and Goebel1 argue against the vasospasm theory, 
and state that functional imaging studies have proved that 
cortical oligaemia rather than ischaemia occurs after a 
wave of spreading cortical depression. They suggest that 
migraine is primarily a neurogenic rather than a vasogenic 
disorder.
This proposal led to the development of a further theory 
by Cutrer and Baloh,13 which suggests that if the dizziness 
is unrelated to headache, it may be caused by the release 
of neuropeptides (substance P, neurokinin A, and others). 
These peptides may have an excitatory effect on the 
baseline firing rate of the sensory epithelium of the inner 
ear and possibly also on the vestibular nuclei in the pons 
of the brainstem. Prolonged symptoms may be caused by 
neuropeptides diffusing into the extracellular fluid. There 
may also be progression of persistent spontaneous vertigo, 
followed by benign positional vertigo and then motion 
sensitivity.
Furthermore, Lee et al9 report a positive association of a 
progesterone receptor with migraine-associated vertigo. 
Eight of the female patients used the OCP and the remaining 
female was on HRT. This may correlate with the theory of 
an associated progesterone receptor variant in MV. It may 
however lead to an increase in the number of females 
presenting with the diagnosis. (Note that the cessation of 
hormone usage forms part of the treatment of MV.11)
Another theory involves serotonin as an important substrate 
in migraine development. Serotonin may have a direct 
effect on the firing rate of vestibular nucleus neurons.4 This 
may lead to theoretical complications when the incorrect 
diagnosis of panic disorder or anxiety disorder is made, and 
a selective serotonin reuptake inhibitor is prescribed. Note 
that patients with MV may respond to benzodiazepines 
because it is a vestibular suppressant.1
Table IV: Results of this study
Gender Male Female
Number of patients diagnosed 3 9
Definite MV 2 7
Probable MV 1 2
Response to sodium valproate and 
amitriptyline combination 
(3 patients treated), 100% response
1 2
Response to amitriptyline alone 




Table V: Symptoms experienced by patients
Symptoms Number of 
patients





Pressure in ears 2
Speech disturbances 1
Tremor 1
Note that all 12 patients had a history of present or past migraine.
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Over the past decade, genetic defects in ion channels, 
specifically voltage-gated calcium channels, have been 
investigated. This is because an abnormal voltage-gated 
calcium channel gene was identified in familial hemiplegic 
migraine and episodic ataxia type 2.1,2 To date, however, no 
calcium channel defect has been identified in the case of 
MV. Acetazolamide has however been found to be effective 
in the treatment of MV, and this may be due to its effects on 
calcium channels.4
Several neurotransmitters that are involved in the 
pathogenesis of migraine (calcitonin gene-related peptide, 
serotonin, noradrenaline and dopamine) also modulate 
vestibular neurons and may contribute to the pathogenesis.2
The author wishes to propose that both migraine and 
MV may be associated with a dopamine hypersensitivity, 
because the dopamine-blocking effects of tricyclic 
antidepressants and even antiepileptic medications, as well 
as cetirizine and prochlorperazine (used to treat nausea 
related to migraine), may be responsible, in their efficacy 
in treating both migraine in a prophylactic sense, as well 
as preventing or treating MV. Withdrawal of dopamine-
blocking agents such as sulpiride may lead to dopamine 
hypersensitivity with associated dizziness and vertigo as 
well as nausea. Medications that increase the levels of 
dopamine in the brain may similarly lead to dizziness. It 
was found that orthostatic symptoms were more frequent 
in patients who had migraine than in controls (68% vs 
8%). Orthostatic hypotension can by induced by small 
doses of dopamine agonists, such as bromocriptine, and 
counteracted by dopamine antagonists in migraineurs but 
not in controls, suggesting hypersensitivity to dopaminergic 
stimulation as an underlying cause of MV.2,14
Conclusions
We are of the opinion that the prevalence of probable or 
definite MV as presenting complaint in the general population 
may be as high as 1.67%. This figure does however not 
reflect the total patient population that suffers from the 
condition or has suffered from it – this figure may be much 
higher. This may correlate with the 3–3.5% prevalence of 
MV in the USA in the general population.4 Other studies 
have found the lifetime prevalence of the condition to be 
0.98% (95% confidence interval 0.7–1.37%).15
Of those patients treated with migraine prophylactic 
medications, the response was 100%, further supporting 
the diagnosis. We conclude by stating that MD and MV 
are relevant complaints that are often misdiagnosed and 
mismanaged as psychogenic dizziness or anxiety. MD can 
be effectively managed with migraine prophylactic drugs 
without the necessity of neurological referral.  
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